U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Fe.O4S.2H2O
Molecular Weight 187.938
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FERROUS SULFATE DIHYDRATE

SMILES

O.O.[Fe++].[O-]S([O-])(=O)=O

InChI

InChIKey=KFJBRJOPXNCARV-UHFFFAOYSA-L
InChI=1S/Fe.H2O4S.2H2O/c;1-5(2,3)4;;/h;(H2,1,2,3,4);2*1H2/q+2;;;/p-2

HIDE SMILES / InChI

Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O4S
Molecular Weight 98.078
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Fe
Molecular Weight 55.845
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Iron(II) gluconate (also known as a ferrous gluconate) is used in the treatment of hypochromic anemia. The real problem of iron therapy is not the theoretical utilization of iron, or the reticulocyte response, or even the daily increase of hemoglobin. These are important only as they indicate the return of the patients' blood to normal in a reasonably short time without undue inconvenience. Most patients suffering from hypochromic anemia respond well to most forms of iron when administered in adequate dosage. For the patients who cannot tolerate the usual iron compounds, it is important to have a medication which is effective and which causes minimum disturbance. Ferrous gluconate is such a medicament.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Primary
Ferro Sanol Duodenal

Approved Use

Ferro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia.
PubMed

PubMed

TitleDatePubMed
Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: Risk factors for early atherosclerosis.
2011 Jun 10
A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts.
2014
Patents

Sample Use Guides

Unknown
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:45:01 GMT 2023
Edited
by admin
on Sat Dec 16 05:45:01 GMT 2023
Record UNII
G0Z5449449
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FERROUS SULFATE DIHYDRATE
Common Name English
FERROUS SULPHATE DIHYDRATE
Common Name English
IRON(II) SULFATE DIHYDRATE
Systematic Name English
IRON SULFATE DIHYDRATE
Systematic Name English
SULFURIC ACID, IRON SALT (FESO4), DIHYDRATE
Common Name English
IRON SULFATE (FESO4) DIHYDRATE
Common Name English
SULFURIC ACID, IRON(2+) SALT (1:1), DIHYDRATE
Common Name English
Code System Code Type Description
PUBCHEM
18359651
Created by admin on Sat Dec 16 05:45:02 GMT 2023 , Edited by admin on Sat Dec 16 05:45:02 GMT 2023
PRIMARY
CAS
10028-21-4
Created by admin on Sat Dec 16 05:45:02 GMT 2023 , Edited by admin on Sat Dec 16 05:45:02 GMT 2023
PRIMARY
FDA UNII
G0Z5449449
Created by admin on Sat Dec 16 05:45:02 GMT 2023 , Edited by admin on Sat Dec 16 05:45:02 GMT 2023
PRIMARY
SMS_ID
100000144550
Created by admin on Sat Dec 16 05:45:02 GMT 2023 , Edited by admin on Sat Dec 16 05:45:02 GMT 2023
PRIMARY
DRUG BANK
DBSALT002463
Created by admin on Sat Dec 16 05:45:02 GMT 2023 , Edited by admin on Sat Dec 16 05:45:02 GMT 2023
PRIMARY
EPA CompTox
DTXSID60904676
Created by admin on Sat Dec 16 05:45:02 GMT 2023 , Edited by admin on Sat Dec 16 05:45:02 GMT 2023
PRIMARY
EVMPD
SUB171209
Created by admin on Sat Dec 16 05:45:02 GMT 2023 , Edited by admin on Sat Dec 16 05:45:02 GMT 2023
PRIMARY
EVMPD
SUB121234
Created by admin on Sat Dec 16 05:45:02 GMT 2023 , Edited by admin on Sat Dec 16 05:45:02 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY